Navigation Links
Transitioning from Bench into Clinical Phase, new webinar hosted by Xtalks
Date:8/26/2014

Toronto, Canada (PRWEB) August 26, 2014

Historically, drug development has faced a number of challenges and the list continues to grow – high attrition rate, low productivity, patent expiry, rising costs of research and development, high regulatory hurdles and increasing concern about adverse side effects. It has also become clear that the traditional business model of pharmaceutical companies is no longer sustainable. Pharmaceutical companies are now seeking to find better ways to reduce operational costs and increase output of new drugs through innovation within research and development.

Drug research and development is a dynamic process, requiring integration of activities across a number of preclinical scientific disciplines for successful progression of therapeutic candidates. The presentation will review the critical challenges in pharmaceutical R&D and highlight how innovative approaches can help to overcome these hurdles. Dr. Yan will also share some cases to illustrate how Covance has helped its partners reach their unique milestones by applying a seamless and strategic approach.

This webinar is part of a series presented by Covance titled “Insights on Improving Global Drug Development from Bench to Commercialization.” For more information about the series or to register for this webinar visit: Transitioning from Bench into Clinical Phase.

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Contact:
Michelle Tran
Tel: +1 (416) 977-6555 ext 352
Email: mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2014/08/prweb12116402.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Oklahoma State Medicaid Adopts Drug Price Benchmark, PAC
2. FarHawk Marketing Services Represents IonBench™ and MS Noise™ at the Greater Boston Mass Spectrometry Discussion Group Corporate Night October 3rd
3. Xinmeiya Technology Releases Their 5C7-195 Benchtop Thermoelectric Controller
4. AEgis Technologies Announces Official Launch of ADME WorkBench Software for Pharmacokinetics Prediction
5. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
6. BioInformatics, LLC Deploys RateMyProduct™ to Rate Benchtop Real-time PCR Machines
7. Global Catalysts Industry 2013-2018: Trend, Profit, and Forecast Analysis - Benchmark the Worlds Top 5 Drug Companies
8. InspireMD To Participate In Benchmark Investor Conference On May 30th
9. HealthSparq to Reveal New Healthcare Transparency Benchmark Study at AHIP Institute 2013
10. Benchmark Research Honored With Industry Accolades
11. PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017   Biostage, Inc. (Nasdaq: ... company developing bioengineered organ implants to treat cancers and ... announced today the closing on February 15, 2017 of ... common stock and warrants to purchase 20,000,000 shares of ... The offering was priced at $0.40 per share of ...
(Date:2/16/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, today announced it has completed ... into a $5 million credit facility with Silicon ... capital for general corporate purposes to further Dermata,s ... of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)...  Windtree Therapeutics, Inc. (Nasdaq: WINT ... KL4 surfactant therapies for respiratory diseases, announced today ... that aerosolized KL4 surfactant reduced lung inflammation and ... model. The Company believes that these preclinical data ... supports the role of KL4 surfactant as a ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... industry leading Biochemistry Services specifically targeting the rapidly growing needs of the ... the biochemical and biosimilar characterization , product-related impurity characterization, aggregation ...
Breaking Biology Technology:
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
(Date:1/18/2017)...  In vitro diagnostic (IVD) companies were very active ... and Kalorama Information expects that trend to continue – ... Generally, uncertainty in reimbursement and healthcare reform in ... the acquisitions landscape. Instead of looking to buy technology, ... outside of their home country and also to increase ...
(Date:1/12/2017)...  New research undertaken by Fit Small Business ... participants were simply asked which office technology had they not ... standard issue.  Insights on what will be key ... futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
Breaking Biology News(10 mins):